PAX8 Antibody - C-terminal region (ARP34179_P050)
- Known as:
- PAX8 Antibody - C-terminal region (ARP34179_P050)
- Catalog number:
- arp34179_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- PAX8 Antibody - C-terminal region (ARP34179_P050)
Related genes to: PAX8 Antibody - C-terminal region (ARP34179_P050)
- Gene:
- PAX8 NIH gene
- Name:
- paired box 8
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 2q14.1
- Locus Type:
- gene with protein product
- Date approved:
- 1998-11-16
- Date modifiied:
- 2017-07-07
Related products to: PAX8 Antibody - C-terminal region (ARP34179_P050)
Related articles to: PAX8 Antibody - C-terminal region (ARP34179_P050)
- Paired box protein Pax-8 (PAX8) is a critical lineage marker and master regulator of transcription in high-grade serous ovarian carcinoma (HGSC)-the most common subtype of epithelial ovarian cancer-driving cell proliferation and migration and resisting apoptosis. This study aimed to elucidate the mechanism of action of PAX8 in this disease. By performing an unbiased analysis of PAX8-regulated genes, we discovered two PAX8-regulated genes-coiled-coil domain-containing protein 80 (CCDC80) and cluster of differentiation 276 (CD276) antigen (also known as B7-H3)-that mediate PAX8 activity and play key cancer cell autonomous roles in this disease. Our findings indicate that PAX8 negatively regulates CCDC80, a novel cell autonomous tumor suppressor in HGSC. We demonstrate that CCDC80, localized to the nucleus, significantly reduces HGSC tumor growth and metastasis in vivo in a mouse model. Notably, CCDC80 exerts its function by suppressing the expression of the immune checkpoint protein B7-H3. However, in HGSC, B7-H3 is predominantly cytoplasmic and promotes HGSC proliferation and migration independent of its immune role. Additionally, PAX8 positively regulates B7-H3 expression in a CCDC80-independent manner, underscoring the multifaceted oncogenic role of PAX8. This study highlights the complex regulatory network involving PAX8, CCDC80, and B7-H3 in HGSC progression. Targeting this signaling pathway may provide a novel therapeutic strategy to improve treatment outcomes for patients with epithelial ovarian cancer. B7-H3, which is currently targeted in clinical trials, shows promise as HGSC target for therapy. - Source: PubMed
Publication date: 2026/04/21
Saleh AyaMedina-Itzhaki NitzanChekov MilenaGal-Swisa EdenGabesh-Wahabi RobaSavyon InbarNaroditsky InnaKenny Hilary AFares BasemKorsensky LinaGirsh EinavBerger LironPerets Ruth - Endometriosis (EM) is a chronic, estrogen-dependent disease that lacks reliable noninvasive diagnostic biomarkers. This study was aimed at evaluating the diagnostic value of PAX8 using integrated transcriptomic and machine learning analyses. - Source: PubMed
Publication date: 2026/04/17
Zhu XiaoliZhong LiXu YanlinZou YuanxiaLiu ManyunTong Xiaoqian - Clear cell renal cell carcinoma (ccRCC) is known to be the most common histological subtype of renal cell carcinoma, with a well-known potential for distant metastasis. Common metastatic sites are the lungs, liver, bones, and brain; however, metastasis to the urinary bladder is exceptionally rare. We describe a 64-year-old man with a history of high-grade ccRCC who developed painless gross hematuria six months after undergoing right radical nephrectomy. Cystoscopic evaluation revealed two polypoidal bladder masses. Histopathological and immunohistochemical analyses confirmed metastatic ccRCC (positive for carbonic anhydrase IX (CAIX), paired-box gene 8 (PAX8), and cluster of differentiation 10 (CD10)). The patient was managed by transurethral resection of bladder tumor (TURBT) followed by targeted therapy with sunitinib (37.5 mg). He remains disease-free at one-year follow-up. This case underscores the importance of considering metastatic recurrence in patients with a prior history of RCC who present with new-onset urinary tract symptoms. Although rare, bladder metastasis should be included in the differential diagnosis. The underlying mechanism remains speculative, with possible routes including hematogenous spread, retrograde venous dissemination, or direct seeding. ccRCC can metastasize to unusual sites, including the urinary bladder. Early recognition through comprehensive imaging and immunohistochemical evaluation is essential for timely diagnosis and management. - Source: PubMed
Publication date: 2026/03/17
Garg ShreyashMittal AnkurPanwar Vikas KSingh Deelip KumarTekwani Ashish V - To analyze the clinicopathological features of low-grade oncocytic tumor of the kidney (LOT) and to explore its cellular origin, immunohistochemical, and molecular characteristics. - Source: PubMed
Publication date: 2026/04/13
Zhao JingWang YajieHuang JianJin XuCai YanyanLu YifanJiang TaoGan Wenjuan - BackgroundMesonephric-like adenocarcinoma (MLA) is a rare type of Müllerian carcinoma that poses significant diagnostic challenges, especially at extrauterine sites. Its morphologic and immunophenotypic overlap with other carcinomas can lead to diagnostic confusion or misclassification.Patient PresentationWe describe a 55-year-old woman with a history of endometriosis who developed peritoneal MLA infiltrating the bowel wall, accompanied by nodal and hepatic metastases. The tumor displayed diverse architectural patterns and was composed of cuboidal to columnar cells with moderate cytologic atypia and vesicular chromatin. Immunohistochemistry showed positivity for keratin, PAX8, and TTF-1, with focal positivity for GATA3 and luminal CD10, and focal weak ER staining in <5% of cells; PR was negative. Focal thyroglobulin expression was also present. Molecular testing revealed a p.G12V activating mutation.DiscussionMLA has a broad differential diagnosis and is often misinterpreted as other neoplasms. Accurate diagnosis requires an integrated assessment of morphology, immunophenotype, and molecular profile. The peritoneal location, particularly in association with endometriosis, raises the possibility of a peritoneal origin.ConclusionPeritoneal MLA is exceptionally rare. Pathologists should consider MLA in the differential diagnosis of peritoneal tumors, particularly those arising in the setting of endometriosis, to ensure accurate classification and appropriate clinical management. - Source: PubMed
Publication date: 2026/04/16
Mohamed Khaled SabryElfatairy KareemCrow JenniferHolloway StevenLucas Elena